BeiGene
BGNE
#881
Rank
โ‚น1.860 T
Marketcap
โ‚น16,946
Share price
1.71%
Change (1 day)
5.70%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : โ‚น196.80 B

According to BeiGene 's latest financial reports the company's total liabilities are โ‚น196.80 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚น188.80 B14.31%
2022-12-31โ‚น165.16 B-7.77%
2021-12-31โ‚น179.07 B41.65%
2020-12-31โ‚น126.42 B180.17%
2019-12-31โ‚น45.12 B30.78%
2018-12-31โ‚น34.50 B49.18%
2017-12-31โ‚น23.12 B543.35%
2016-12-31โ‚น3.59 B27.48%
2015-12-31โ‚น2.82 B60%
2014-12-31โ‚น1.76 B-43.55%
2013-12-31โ‚น3.12 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚น1.01 B-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น49.04 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA